CorriXR Therapeutics, Inc.
June 16, 2025
Company Presentation
Oncology
CorriXR Therapeutics is an oncology-focused biotherapeutics company developing genetic medicines to transform the treatment of solid tumors. CorriXR uses a proprietary in vivo gene editing tool to disable transcription factor NRF2, which controls 200+ genes responsible for creating a pro-oncogenic tumor microenvironment. Knockout of NRF2 disrupts cancer cell survival mechanisms and sensitizes them to standard of care (SOC) treatments. Preclinical POC has been successfully demonstrated, and IND-enabling work is ongoing in the company’s lead program CXR101 for the treatment of head & neck squamous cell carcinoma. CXR101 is designed to seamlessly integrate with current SOC and can be used either as a neoadjuvant or in combination with chemo, radiotherapy or immunotherapy treatment. CXR101 has the potential to improve treatment efficiency at lower doses, increasing patient eligibility and reducing dropouts due to side effects, ultimately leading to improved patient outcomes.
Company HQ City:
Newark
Company HQ State:
Delaware
Company HQ Country:
United States
Year Founded:
2022
Lead Product in Development:
CXR101
CEO
Eric B. Kmiec, Ph.D.
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
IND submission
What is your next catalyst (value inflection) update?
March 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}